{"id":"W4311929403","doi":"10.1016/j.clcc.2022.11.003","title":"ROCKET: Phase II Randomized, Active-controlled, Multicenter Trial to Assess the Safety and Efficacy of RRx-001 + Irinotecan vs. Single-agent Regorafenib in Third/Fourth Line Colorectal Cancer","year":2022,"lang":"en","type":"article","venue":"Clinical Colorectal Cancer","topic":"Immune cells in cancer","field":"Immunology and Microbiology","cited_by":14,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"","keywords":"Regorafenib; Irinotecan; Medicine; Randomized controlled trial; Colorectal cancer; Internal medicine; Oncology; Pharmacology; Cancer","routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002655722,0.00237956,0.002712638,0.0006377274,0.0003807982,0.001217011,0.001334332,0.001502256,0.01124262],"category_scores_gemma":[0.002028576,0.0007020961,0.00182102,0.0005569248,0.00109998,0.001374214,0.0004812929,0.003301591,0.001508467],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001045532,"about_ca_system_score_gemma":0.001710666,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008214845,"about_ca_topic_score_gemma":0.002371136,"domain_scores_codex":[0.9991878,0.000486762,0.00003462756,0.0001242433,0.00006088893,0.0001056807],"domain_scores_gemma":[0.9989809,0.0002138306,0.0004105081,0.00007999326,0.00004687351,0.0002677616],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9737148,0.005564364,0.0008533891,0.0005654038,0.0007590699,0.00005683133,0.00003088192,0.0006548243,0.00349865,0.0001947636,0.002000541,0.01210643],"study_design_scores_gemma":[0.9435657,0.05303602,0.001200063,0.00001993875,0.000372626,0.0000770101,0.00001467423,0.0004456933,0.000410195,0.000130791,0.0007143317,0.00001284604],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9766679,0.005061602,0.001008602,0.001524217,0.0006695612,0.006300732,0.004008497,0.0004502833,0.004308693],"genre_scores_gemma":[0.9696658,0.003006585,0.002620968,0.001783266,0.0007451564,0.009338728,0.004362661,0.00007390136,0.00840288],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01124262,"threshold_uncertainty_score":0.03761035,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04694934307638858,"score_gpt":0.3620586741039091,"score_spread":0.3151093310275205,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}